REGENERX BIOPHARMACEUTICALS, INC. RegeneRx Biopharmaceuticals, Inc. reported that researchers have demonstrated the therapeutic efficacy of Thymosin Beta 4 (Tß4) as a combination treatment against hyperglycemia (diabetic)-induced changes in human corneal epithelial cells. The research was presented at the Association for Research in Vision and Ophthalmology (ARVO) 2022 meeting, held May 1-4, 2022, in Denver, Colorado. The research team included scientists and physicians from Wayne State University School of Medicine in Detroit, MI; the University of Central Florida College of Health Professors and Sciences in Orlando, FL; and Mansoura University in Mansoura, Egypt.
The research was funded by the National Institutes of Health, the Eversight Center for Vision and Eye Banking Research, and Research to Prevent Blindness.
